大脑缩不能预测渐进性超核的临床进展
Andrea Quattrone1,2,3, Nicolai Franzmeier4,5,6, Hans-Jürgen Huppertz7
1Department of Neurology, University Hospital, LMU Munich, Munich, Germany.
概括
基线临床严重程度和大脑缩并不能预测逐渐超核性 (PSP) 的个体进展. 这表明基于MRI的患者分层可能不必用于未来的PSP临床试验.
科学领域:
- 神经科学
- 临床神经学
- 医学成像
背景情况:
- 进展性超核性 (PSP) 的临床试验通常使用临床进展率作为主要终点.
- 预测个体疾病的发展轨迹对于有效的临床试验设计和患者管理至关重要.
研究的目的:
- 调查基线临床严重程度和区域大脑缩是否可以预测PSP-理查德森综合征 (PSP-RS) 的临床进展.
- 评估机器学习模型在预测个体患者进展率方面的有用性.
主要方法:
- 一项纵向多队列研究包括309名来自临床试验安慰剂组和Describe PSP队列的PSP-RS患者.
- 分析了基线临床数据,体积核磁共振和1年PSP评分尺度 (PSPRS) 变化之间的关联.
- 使用机器学习模型预测个体的临床发展轨迹.
主要成果:
- 在PSP-RS患者中,每年平均PSPRS得分增加10. 3分.
- 额叶体积与随后的临床进展有着最强烈的关联 (β: - 0.34, P < 0.001).
- 机器学习模型未能准确预测个体进展率 (R2 < 0.15).
结论:
- 无论是基线临床严重程度还是脑缩都不能可靠地预测PSP-RS的个体临床进展.
- 在未来的PSP临床试验中,可能不需要基于MRI的患者分层.
- 结果可以为试验设计和患者选择策略提供信息.
相关概念视频
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666


